RxDoctor Payments Data

Dannaly Reyes Baerga, MD

Neurology · St Petersburg, FLNPI 1750623997

Payments from drug & device makers

$35,577in general payments, 2019–2025

Across 464 payments — averaging $76.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$19K
  • AbbVie$5K
  • Pfizer$4K
  • Novartis$601
  • AstraZeneca$551
  • UCB, Inc.$548
  • plus $6K from 54 others

What the payments were for

  • Consulting fees$3,27524%
  • Speaking & faculty fees$230%
  • Food & beverage$10,40976%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astrazeneca UK Limited1$19,020
AbbVie(2 entities)99$4,687
Pfizer35$3,825
Novartis32$601
AstraZeneca(2 entities)21$551
UCB, Inc.18$548
GE HealthCare18$491
Genentech USA, Inc.15$453
Lundbeck LLC14$417
Biogen15$337
Amgen(2 entities)14$328
Takeda Pharmaceuticals U.S.A., Inc.11$327
Argenx US, Inc.7$266
Neurocrine Biosciences, Inc.13$265
Catalyst Pharmaceuticals, Inc.8$241
Lilly USA, LLC12$233
Teva Pharmaceuticals USA, Inc.15$233
Tanabe Pharma America, Inc.8$226
CSL Behring7$181
Biohaven Pharmaceuticals, Inc.3$163
Portola Pharmaceuticals, LLC9$158
Acorda Therapeutics, Inc6$147
Silk Road Medical, Inc.1$138
Upsher-smith Laboratories LLC6$120
Eisai Inc.6$120
SK Life Science, Inc.3$103
Jazz Pharmaceuticals Inc.4$96
Vanda Pharmaceuticals Inc.4$95
Merz Pharmaceuticals, LLC4$91
Sumitomo Pharma America, Inc.5$84
Biohaven Pharmaceutical Holding Company Ltd.3$67
Alnylam Pharmaceuticals Inc.2$53
Bristol Myers Squibb3$51
Harmony Biosciences LLC2$49
Acadia Pharmaceuticals Inc2$48
Banner Life Sciences, LLC2$48
Johnson & Johnson(2 entities)2$48
Axsome Therapeutics, Inc.2$47
Impel Pharmaceuticals LLC2$45
Xeris Pharmaceuticals, Inc.2$45
Akcea Therapeutics, Inc.1$44
Avanir Pharmaceuticals, Inc.3$42
Corium, LLC2$40
Zyla Life Sciences, Inc.3$40
Sunovion Pharmaceuticals Inc.2$38
Sanofi2$38
E.r. Squibb & Sons, L.L.C.1$33
Mallinckrodt Hospital Products Inc.1$27
Aucta Pharmaceuticals, Inc.2$27
Otsuka America Pharmaceutical, Inc.1$26
C2n Diagnostics, LLC1$24
Microtransponder, Inc.1$22
Neurelis, Inc.1$22
Amneal Pharmaceuticals LLC1$18
Cycle Pharmaceuticals Inc1$18
EMD Serono, Inc.1$16
Idorsia Pharmaceuticals US Inc1$16
Nevro Corp.1$13
Collegium Pharmaceutical, Inc.1$13
Medtronic1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,577 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$133,130
Medicare patients
244
Services billed
11,962

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe79$66,375
UbrelvyUbrogepant34$47,302
QuliptaAtogepant38$42,012
BotoxOnabotulinumtoxina24$41,411
Nurtec OdtRimegepant Sulfate18$30,557
Emgality PenGalcanezumab-Gnlm35$29,283
XareltoRivaroxaban17$15,340
Emgality SyringeGalcanezumab-Gnlm13$9,558
Sumatriptan Succinate59$4,087
Lacosamide29$3,702
Memantine Hcl102$2,181
Rivastigmine16$1,914
Gabapentin135$1,906
AmantadineAmantadine Hcl17$1,528
Donepezil Hcl144$1,518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$4,687$130,72496 claims
PfizerNurtec Odt$3,825$30,55718 claims
Johnson & JohnsonXarelto$48$15,34017 claims
Upsher-smith Laboratories LLCTopiramate$120$25535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,434 neurology providers in Florida.

Other neurology in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →